Search Results
Your search for Hope matches 3187 pages
Showing 2051 - 2100Expert Point of View: Ashish Saxena, MD, PhD
After the data were presented, Ashish Saxena, MD, PhD, Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at the NewYork-Presbyterian Hospital, New York, weighed in on the CA209-003 study. “The results of this trial are exciting and give hope to...
CDK4/6 Inhibitors: Where They Are Now and Where They Are Headed in the Future
Geoffrey I. Shapiro, MD, PhD, Director of the Early Drug Development Center at the Dana-Farber Cancer Institute, Boston, explained the current research initiatives involving cyclin D–dependent kinase (CDK) 4/6 inhibitors. Mechanism of Action How do CDK4/6 inhibitors work at the cellular level in...
Continuing Education Information
This CE/CME/CEU-accredited supplement is jointly provided by To earn credit/contact hours, you must read all the articles in this supplement and then go to: https://education.annenberg.net/cdk46inhibition Release date: May 10, 2017 Expiration date: May 10, 2018Annenberg Center for Health...
ASCO Applauds Congress for Providing Additional $2 Billion in NIH Funding
On May 1, Congress announced a bipartisan 2017 budget deal that contains a $2 billion increase in medical research funding for the National Institutes of Health (NIH), including $475 million more for the National Cancer Institute. The budget also maintains funding for cancer control programs at the ...
European Commission Approves Nivolumab for Head and Neck Squamous Cell Carcinoma Progressing on or After Platinum-Based Therapy
On April 28, the European Commission approved nivolumab (Opdivo) as monotherapy for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults with disease progression on or after platinum-based therapy. Nivolumab is the first and only immuno-oncology treatment that has...
Second Cancers May Be Deadlier in Pediatric, Adolescent, and Young Adult Patients
Second cancers in children as well as adolescents and young adults (AYAs) are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients aged 15 to 39 years overall, according to a new study by University of California (UC), Davis...
Using Geriatric Assessment Strategies to Inform Patient-Centered End-of-Life Care
End-of-life care in any patient with cancer is challenging for the patient, family, and physician. Issues faced at the end of life include pain, depression, loss of dignity, and hopelessness. In the geriatric patient, additional complexities are present in the form of comorbid conditions,...
Equivalent Response Rates With Trastuzumab or a Trastuzumab Biosimilar Plus Taxane in HER2-Positive Metastatic Breast Cancer
In part 1 of the Heritage study, a phase III equivalence trial reported in JAMA, Hope S. Rugo, MD, of the University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, and colleagues found that treatment with trastuzumab (Herceptin) or a proposed trastuzumab biosimilar...
Treating Human Immunodeficiency Virus–Related Lymphoma
Alexandra Levine, MD, MACP, is Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, Duarte, California, and has been on the front lines of the AIDS epidemic from the beginning—before the disease even had a name. Dr. Levine spoke with The ASCO Post about ...
Treatment of Diffuse Large B-Cell Lymphoma Continues to Evolve
Although the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) has improved with R-CHOP—the addition of rituximab (Rituxan) to the cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy regimen—one-third of patients still relapse after therapy, and patients with the ...
NCCN Foundation Board of Directors Names New Leadership
The NCCN Foundation® has named Gena Cook, Cofounder and Chief Executive Officer of Navigating Cancer, as Chair of the National Comprehensive Cancer Network® (NCCN®) Foundation Board of Directors. Ms. Cook, who was elected to the Board in 2010, succeeds Ellen O. Tauscher, former U.S....
Combination of Atezolizumab and Bevacizumab in PD-L1–Positive Patients With Metastatic Kidney Cancer
The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) appears to be promising in the first-line treatment of patients with metastatic renal cell carcinoma, according to results of a phase II trial presented at the 2017 Genitourinary Cancers Symposium.1 Despite the failure of the...
Expert Point of Review: Amrita Krishnan, MD
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at the City of Hope in Duarte, California, told The ASCO Post that the most exciting drug in the “New Agents” session she moderated at the 2016 American Society of Hematology (ASH) Annual Meeting...
FNIH Awards Lurie Prize in Biomedical Sciences to David M. Sabatini, MD, PhD
The Foundation for the National Institutes of Health (FNIH) has selected David M. Sabatini, MD, PhD, to receive its 5th annual Lurie Prize in Biomedical Sciences for discovery of the mTOR (mechanistic target of rapamycin) cellular pathway as a key regulator of growth and metabolism in response to...
Progress in Defining Molecular Signature for Aggressive Androgen-Indifferent Prostate Cancer
Prostate cancer has lagged behind breast cancer in the identification of predictive and prognostic biomarkers, but the field is catching up. Researchers have identified a molecular signature that can distinguish aggressive prostate cancer that is androgen-indifferent and will have a better response ...
Onset of Diabetes or Its Rapid Deterioration Can Be an Early Warning Sign of Pancreatic Cancer
The onset of diabetes, or a rapid deterioration in existing diabetes that requires more aggressive treatment, could be a sign of early, hidden pancreatic cancer, according to research presented by Autier et al at the 2017 European Cancer Congress (Abstract 540).1 Study Design and Key Findings...
ASCO Honors Researchers, Scientists for Significant Advances in Cancer Treatment and Care
ASCO and the Conquer Cancer Foundation (CCF) proudly announce the winners of ASCO’s Special Awards, the Society’s highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked ...
Medical Groups Unite in Support of March for Science
Twenty-five of the nation’s leading medical groups issued this statement on April 17: As the world's leading organizations representing clinicians, laboratory researchers, and physician-scientists committed to improving patient care, we support the March for Science and its nonpartisan call...
How ASCO’s CancerLinQ Discovery™ Will Help Speed Research Advances and Improve Patient Outcomes
This past November, ASCO announced the launch of CancerLinQ Discovery™, a big data learning platform physicians and researchers can use to analyze highly curated, de-identified, real-world cancer care data sets to broaden their clinical knowledge about specific cancers and eventually improve...
AACR 2017: Telomere Length May Predict Cancer Risk, According to Large Epidemiologic Study
The length of the telomeres that protect the tips of chromosomes may predict cancer risk and be a potential target for future therapeutics, University of Pittsburgh Cancer Institute (UPCI) scientists reported at the 2017 American Association for Cancer Research (AACR) Annual Meeting in...
Thomas E. Starzl, MD, PhD, ‘Father of Modern Transplantation,’ Dies at Age 90
Scientific and clinical pioneers have one thing in common: they move beyond their comfort zone and take calculated risks. One such pioneer, whose calculated risks gave hope to otherwise hopelessly ill people, was Thomas E. Starzl, MD, PhD, who performed the world’s first successful liver...
Increased Recognition of Colorectal Cancer in Young Adults, Even Those Aged 20 to 29, as Evidence Continues to Accumulate
The incidence of colorectal cancer continues to increase among young adults, with the sharpest increase among those aged 20 to 29, according to a recent article in the Journal of the National Cancer Institute.1 This trend has been called disturbing and ominous, but the widely reported results of...
Forging a New Role to Make Curing More Cancers a Reality
For more than 3 decades, Nancy E. Davidson, MD, has dedicated her clinical and research career to better understanding the molecular mechanisms driving the development of breast cancer and to the discovery of more effective therapies to treat the disease. The recipient of an ASCO Young...
ASCO Clinical Practice Guideline Update: Integration of Palliative Care Into Standard Oncology Care
As reported in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline update on integration of palliative care into standard oncology care.1 This update of a 2012 ASCO provisional clinical opinion2 is based on an Expert Panel’s systematic review of data reported between...
ASCO Clinical Practice Guideline on Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers
As reported in the Journal of Clinical Oncology by Saro H. Armenian, DO, MPH, of City of Hope, and colleagues, ASCO has released a clinical practice guideline on prevention and monitoring of cardiac dysfunction in survivors of adult cancers.1 Recommendations were developed by an expert panel...
Fred Hutchinson’s Paulovich Laboratory to Lead Protein Assay Work for National Cancer Moonshot
The Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network, which represents a partnership among the National Cancer Institute (NCI), the Department of Defense, and the Department of Veterans Affairs, has tapped the Paulovich Laboratory at Fred Hutchinson Cancer Research...
CancerLinQ: Big Data for Quality Benchmarking
At this year’s ASCO Quality Care Symposium, CancerLinQ’s Vice President and Medical Director, Robert S. Miller, MD, shed light on CancerLinQ’s current and future value in the oncology community.1 Dr. Miller opened by explaining to the audience that CancerLinQ™ is an instrument for quality...
Pediatric Oncology Patient and Parent Attitudes on Early Palliative Care Integration
Few pediatric oncology patients or their parents expressed negative attitudes toward early integration of palliative care during cancer treatment, according to a study by Levine et al reported in JAMA Oncology. Study Details The study involved completion of surveys by 129 patient-parent dyads...
New Supportive Care Resources From NCCN Help Patients With Cancer Confront Distress
All patients with cancer experience some level of distress associated with their cancer diagnosis and the effects of the disease and its treatment—regardless of the stage of disease. Not only does distress affect a patient’s mental and psychosocial well-being, but because distress is a...
Arti Hurria, MD, Named Vice Provost at City of Hope
Geriatrician-oncologist Arti Hurria, MD, has been named Vice Provost for Clinical Faculty at City of Hope. “I spent most of my formative years at City of Hope and was very fortunate,” said Dr. Hurria, who’s been at the medical center for 10 years. “I had mentors who helped me along the way and...
Chief Clinical Officer’s Distinguished Chair Created at City of Hope to Honor Alexandra M. Levine, MD, MACP
A significant philanthropic gift from the Campbell family of Las Vegas, Nevada, will establish a new endowed Chair to honor City of Hope’s former Chief Medical Officer Alexandra M. Levine, MD, MACP. The recipient of the Deana and Steve Campbell Chief Clinical Officer’s Distinguished Chair, to be...
Developing Better Multidisciplinary Strategies
“More than any other disease, head and neck cancer requires constant interplay between a number of different specialties,” Sandeep Samant, MD, Chief, Head and Neck Surgery, Northwestern Medicine, and Chair of the Multidisciplinary Head & Neck Symposium sponsored by the Robert H. Lurie...
Dexamethasone Mouthwash in Preventing Everolimus-Related Stomatitis in Women With Breast Cancer
In the phase II SWISH study reported in The Lancet Oncology, Rugo et al found that use of a dexamethasone-based mouthwash may prevent everolimus-related stomatitis in postmenopausal women receiving everolimus (Afinitor) for hormone receptor–positive, HER2-negative metastatic breast cancer....
Thoracic 2017: Proton Therapy Offers New Treatment Possibility for Recurrent Lung Cancer
A new study offers hope for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment. In the largest analysis to date of reirradiation using intensity-modulated proton therapy for lung and other thoracic tumors, more than three-fourths of patients ...
Thoracic 2017: Genetic Profile of Treatment-Resistant Lung Cancer More Variable Than Previously Thought
The genetic mutations underlying treatment resistance in non–small cell lung cancer (NSCLC) are more complex and dynamic than previously thought. Analysis of 355 biopsied tumors from patients who acquired resistance to epidermal growth factor receptor (EGFR) inhibitors, the most common form...
FDA Approves Pembrolizumab for Relapsed or Refractory Classical Hodgkin Lymphoma in Adult and Pediatric Patients
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, for the treatment of adult and pediatric patients who have refractory classical Hodgkin lymphoma or have relapsed after three or more prior lines of...
Factors Associated With Early Death in Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Green et al found that risk factors for death within 1 month of diagnosis of childhood cancer included age up to 1 year, specific diagnoses, and minority race/ethnicity. The study involved analysis of data from SEER (Surveillance,...
ASCO Honors Researchers and Scientists for Significant Advancements in Cancer Treatment and Care
ASCO and the Conquer Cancer Foundation of ASCO (CCF) have proudly announced the winners of ASCO's Special Awards, the Society's highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders...
Clinical Practice Committee, State Affiliate Council Support Innovative Clinical Research—And So Can You
ASCO’s Clinical Practice Committee (CPC) and State Affiliate Council (SAC) have a history of supporting the Conquer Cancer Foundation of ASCO (CCF) Young Investigator Award (YIA) program. Individual members of the Clinical Practice Committee and State Affiliate Council, as well as ASCO State...
Close to Home: Dr. Rick Boulay’s Experience With Cancer Survivorship and Caregiving
Richard ‘Rick’ Boulay, MDChief of Gynecologic Oncology Institution: Lehigh Valley Health Network Member since: 2016 Three years ago, Richard ‘Rick’ Boulay, MD, Chief of Gynecologic Oncology at Lehigh Valley Health Network, walked onto the stage at TEDx Lehigh River and confronted his audience...
Cervical Cancer Mortality Is Higher and Racial Disparity Wider Than Previously Reported
Cervical cancer mortality rates were significantly higher, particularly among black women, when national data were corrected to exclude women who have had hysterectomies. For black women, the cervical cancer mortality rate rose from 5.7 to 10.1 per 100,000 when corrected for hysterectomy, an...
Immunotherapy for Head and Neck Cancer: ‘The Fourth Modality Has Arrived’
“This is a big deal. This is going to change all of oncology, not just head and neck cancer,”1 Tanguy Seiwert, MD, remarked following a summary by Jeffrey Sosman, MD, on advances in immunotherapy for treating cancer.2 Dr. Sosman, Director of the Melanoma Program and Clinical Director of Cancer...
Phase II Trial Evaluates New Gene Therapy for Non–Muscle Invasive Bladder Cancer After BCG
A novel approach using intravesical gene therapy showed promising activity in a phase II trial that enrolled patients with bacillus Calmette-Guérin (BCG)-refractory or -relapsed nonmuscle invasive bladder cancer.1 The rate of high-grade relapse-free survival at 12 months was 35% in patients treated ...
Effect of Scalp Cooling on Hair Loss in Women Receiving Nonanthracycline Chemotherapy for Breast Cancer
In a prospective cohort study reported in JAMA, Rugo et al found that use of a scalp-cooling device reduced hair loss in women receiving nonanthracycline chemotherapy for early-stage breast cancer. Study Details In the study, 101 evaluable patients from 5 U.S. centers with stage I or II breast...
ASCO Quality Care 2017: In-House Specialty Pharmacy at Cancer Center Improves Quality of Care, Reduces Medical Errors
An influx of new oral cancer drugs provides patients with a more convenient and less invasive way to take medication, but such treatments are often associated with adherence challenges and medical errors. New research shows that the addition of an in-house specialty pharmacy at a cancer center in...
SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers
People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20% of cancers...
Bright Future for Osimertinib in EGFR T790M–Positive Lung Cancer
The AURA3 study—reported by Mok and colleagues and reviewed in this issue of The ASCO Post—confirms the dramatic activity of osimertinib (Tagrisso) in patients with advanced epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC) and acquired resistance to prior EGFR...
Study Finds Children, Parents Overreport Adherence to Leukemia Treatment
New research suggests that young patients with acute lymphocytic leukemia (ALL)—the most common type of pediatric cancer—and their parents are likely to report to their physician that they took more of their anticancer medication than they actually did. The study, published by Landier et al in...
Expert Point of View: Jose Leis, MD, PhD
Jose Leis, MD, PhD, of the Mayo Clinic in Arizona, commented on the promise of checkpoint inhibitors in Richter transformation. “At Mayo, we have treated more than 30 patients with programmed cell death protein 1 (PD-1) blockade. We do see that chronic lymphocytic leukemia (CLL) has low expression ...
Payers Weigh the Implications of Multigene Testing Coverage
Innovation in precision medicine has introduced an amalgam of testing options, of which hereditary cancer panels—multigene tests—are a major component. Additionally, the importance of inherited cancer genomics was further bolstered by former President Barack Obama’s Precision...
